此乃要件 請即處理 閣下如對本通函任何方面有任何疑問，應諮詢 閣下之股票經紀或其他註冊證券商、銀行 經理、律師、專業會計師或其他專業顧問。 閣下如已將名下之雲知聲智能科技股份有限公司股份全部售出或轉讓，應立即將本通函及隨 附的代表委任表格交予買主或承讓人或經手買賣或轉讓之銀行、股票經紀或其他代理商， 以便轉交買主或承讓人。 香港交易及結算所有限公司及香港聯合交易所有限公司對本通函之內容概不負責，對其準 確性或完整性亦不發表任何聲明，並明確表示，概不對因本通函全部或任何部分內容而產 生或因依賴該等內容而引致之任何損失承擔任何責任。 UNISOUND AI TECHNOLOGY CO., LTD. 雲知聲智能科技股份有限公司 （於中華人民共和國註冊成立的股份有限公司） （股份代號：9678） 關 於 修 訂《 公 司 章 程 》及 其附件並辦理工商變更登記的議案 關於選舉第三屆董事會非職工代表董事的議案 關於董事薪酬方案的議案 關於授予董事會增發公司股份一般性授權的議案 及 2025 年第三次臨時股東會通告 雲知聲智能科技股份有限公司謹訂於2025年12月10日（星期三）上午10時正於雲知聲智能科 技股份有限公司 ...

Group 1 - The company Yunzhisheng (09678) announced that its second board of directors will expire on December 10, 2025 [1] - Several members of the current board, including Executive Director Li Peng, Non-Executive Directors Kwang Ziping and Wang Cunfu, and Independent Non-Executive Director Chen Hua, will not stand for re-election [1] - The board's nomination committee has proposed the reappointment of Dr. Liang Jiaen, Dr. Huang Wei, Dr. Kang Heng, and Dr. Li Xiaohan as Executive Directors for the third board [1] Group 2 - The company has held its first employee representative meeting of 2025, electing Dr. Liu Shengping as the employee representative director for the third board [2]

Group 1 - The second board of directors of Yunzhisheng (09678) will expire on December 10, 2025 [1] - Several current board members, including executive director Li Peng and non-executive directors Kwang Ziping and Wang Cunfu, will not stand for re-election [1] - The board nomination committee has proposed the reappointment of several individuals for the third board, including Dr. Liang Jiaen and Dr. Huang Wei as executive directors [1] Group 2 - The company has held its first employee representative meeting of 2025, electing Dr. Liu Shengping as the employee representative director for the third board [2]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性或完整性亦不發表 任何聲明，並明確表示概不就因本公告全部或任何部分內容而產生或因倚賴該等內容而引致的任何損失承擔任何 責任。 UNISOUND AI TECHNOLOGY CO., LTD. 雲知聲智能科技股份有限公司 （於中華人民共和國註冊成立的股份有限公司） （股份代號：9678） 公 告 建 議 修 訂《 公 司 章 程 》 建議選舉第三屆董事會非職工代表董事 選舉第三屆董事會職工代表董事 及 暫停辦理股份過戶登記手續 建議修訂《公司章程》 雲知聲智能科技股份有限公司（「本公司」）董事會（「董事會」）謹此宣佈，根據《中華人民 共和國公司法》（「《公司法》」）等法律法規、規範性文件的規定並結合本公司實際情況， 本公司擬對《雲知聲智能科技股份有限公司公司章程》（「《公司章程》」）進行修訂（「本次 章程修訂」），本次章程修訂主要包括細化股東會提案及表決程序、修改董事會組成人數 及補充董事會職權範圍、細化其他高級管理人員的任期、優化會計師事務所的聘任程序 和其他文字修訂等。 董事會將提請本公司2025年第三次臨時股東會（「臨時股東 ...

雲知聲智能科技股份有限公司 董事會提名委員會職權範圍 1 第三章 職責權限 第一章 總則 第一條 為規範公司董事和高級管理人員的產生，優化董事會組成，完善公司治理結 構，根據《中華人民共和國公司法》、《香港聯合交易所有限公司證券上市規則》和《雲知 聲智能科技股份有限公司章程》（以下簡稱「《公司章程》」）等有關規定，公司設立董事會 提名委員會，並制定本職權範圍。 第二條 董事會提名委員會是董事會設立的專門工作機構，主要負責對公司董事、總經 理和其他高級管理人員的人選、甄選標準和程序等事項進行選擇並提出建議。 第三條 《公司法》和《公司章程》關於董事義務的規定適用於提名委員會委員。 第二章 人員組成 第四條 提名委員會由至少3名董事組成，其中獨立非執行董事佔多數，且至少一名成 員的性別須與提名委員會其他成員不同。 第五條 提名委員會委員由董事長、二分之一以上獨立非執行董事或者全體董事的三 分之一以上提名，並由董事會選舉產生。 第六條 提名委員會設主席一名，由獨立非執行董事或董事會主席擔任，主席負責主持 委員會工作，擔任召集人，主席由董事會批准產生。 第七條 提名委員會任期與董事會任期一致，委員任期屆滿，連選可以連 ...

董事會薪酬委員會職權範圍 第一章 總則 第一條 為進一步建立健全公司董事及高級管理人員的考核和薪酬管理制度，完善公司 治理結構，根據《中華人民共和國公司法》、《香港聯合交易所有限公司證券上市規則》 （以下簡稱「《上市規則》」）和《雲知聲智能科技股份有限公司章程》（以下簡稱「《公司章 程》」）等有關規定，公司設立董事會薪酬委員會，並制定本職權範圍。 雲知聲智能科技股份有限公司 第二條 薪酬委員會是董事會設立的專門工作機構，主要負責制定、審查公司董事及高 級管理人員的薪酬政策與方案，負責制定公司董事及高級管理人員的考核標準並進行 考核，對董事會負責。 第三條 《公司法》、《上市規則》和《公司章程》關於董事義務的規定適用於薪酬委員會 委員。 第二章 人員組成 第四條 薪酬委員會成員由至少3名董事組成，其中獨立非執行董事佔多數。 第五條 薪酬委員會委員由董事長、二分之一以上獨立非執行董事或者全體董事的三 分之一以上提名，並由董事會選舉產生。 第六條 薪酬委員會設主席一名，擔任召集人，由獨立非執行董事擔任，負責主持委員 會的工作。主席由董事會批准產生。 第七條 薪酬委員會任期與董事會任期一致，委員任期屆滿，連選可以連任 ...

雲知聲智能科技股份有限公司 董事會審核委員會職權範圍 第一章 總則 第一條 為強化雲知聲智能科技股份有限公司（以下簡稱「公司」）董事會決策功能，做 到事前審計、專業審計，確保董事會對高級管理人員的有效監督，完善企業管治結構， 根據《中華人民共和國公司法》（以下簡稱「《公司法》」）、《香港聯合交易所有限公司證券 上市規則》（以下簡稱「《上市規則》」）和《雲知聲智能科技股份有限公司章程》（以下簡稱 「《公司章程》」）等相關規定，制定本職權範圍。 第二條 董事會審核委員會是董事會設立的專門工作機構，主要負責公司內、外部審計 的溝通、監督和核查工作。 公司設立的內部審計部門對審核委員會負責，向審核委員會報告工作。 第三條 《公司法》、《公司章程》和《上市規則》關於董事義務的規定適用於審核委員會 委員。 第二章 人員組成 第四條 審核委員會由至少3名董事組成，全部為非執行董事，其中獨立非執行董事佔 多數，且至少應有一名獨立非執行董事是會計專業人士且符合《上市規則》對具備適當 專業資格或具備適當的會計或相關財務管理專長的獨立非執行董事的要求。 第五條 審核委員會委員由董事長、二分之一以上獨立非執行董事或者全體董事的三分 ...

Core Insights - Cloud Wisdom (09678.HK) successfully listed on the Hong Kong Stock Exchange as the "first AGI stock" on June 30, 2025, and was included in the Hong Kong Stock Connect on September 8, indicating strong market confidence in its AGI industrialization value [1] - On October 28, the company achieved "international leading" certification for three core technologies at a technology achievement appraisal meeting in Beijing, further solidifying its technological leadership across four key tracks [1][5] Technology Validation - The technology achievement appraisal was organized by the Chinese Association for Artificial Intelligence, featuring a strong panel of experts, including Liu Chenglin from the Chinese Academy of Sciences and foreign academician Mei Tao from the Canadian Academy of Engineering [3] - The expert panel recognized Cloud Wisdom's three technologies: "multi-modal medical vertical large model," "chip-side small model refinement," and "multi-modal intelligent digital human," all reaching "international leading" status, indicating significant global innovation and superior core metrics compared to similar technologies [5] Leading Technologies - With the previously certified "AI voice free speech technology," Cloud Wisdom has established a comprehensive leadership across four key tracks [6] - The "multi-modal medical vertical large model" achieves over 90% accuracy in detecting liver focal lesions and has excelled in multiple authoritative medical evaluations, outperforming human average scores in clinical qualification exams [6] - The "chip-side small model refinement" technology has achieved a breakthrough in model lightweighting, maintaining high accuracy under low power conditions while reducing resource consumption by over 100 times [6] - The "multi-modal intelligent digital human" technology addresses industry challenges such as unnatural dynamic performance, with applications in customer service and education [6] - The "AI voice free speech technology" has successfully enhanced smart home appliances, facilitating more convenient human-machine interactions [6] - Cloud Wisdom has developed a four-layer technology architecture, integrating "general foundation - professional intelligent body - edge chip optimization - Atlas infrastructure," creating a closed loop of technology, scenarios, and data [6] - The company has established deep collaborations with several leading enterprises, achieving large-scale implementation in smart healthcare and smart living sectors [6]

Core Insights - The 2025 Xiamen Industrial Development Conference recognized outstanding companies in various categories, with Cloud Wisdom (09678.HK) winning the "Technology Innovation Golden Bull Award" for its achievements in artificial intelligence [1][3]. Company Achievements - Cloud Wisdom was listed on the Hong Kong Stock Exchange on June 30, 2025, becoming the "first AGI stock on the Hong Kong Stock Exchange" [4]. - The company has developed a comprehensive technology system covering large models, intelligent computing platforms, multimodal interaction, and AI chips, showcasing its strong technical capabilities [4]. - Its self-developed "Shanhai Large Model" has excelled in multiple authoritative evaluations, ranking among the global top tier in general performance assessments and achieving high rankings in specialized medical evaluations [4]. Industry Recognition - The Golden Bull Award has been a prestigious recognition in China's capital market since its inception in 1999, focusing on companies demonstrating exceptional strength and foresight in innovation and industry transformation [3]. - The award this year particularly emphasized cutting-edge technology fields such as artificial intelligence, new energy, and biomedicine, highlighting the industry's acknowledgment of Cloud Wisdom's technological accumulation and innovation capabilities in AGI [3]. Strategic Collaborations - In 2025, Cloud Wisdom has made significant strides in international cooperation and regional expansion, signing memorandums of cooperation with the government of Vanuatu and other organizations, as well as establishing strategic partnerships with health authorities in Guangxi [7]. - These collaborations are expected to strengthen Cloud Wisdom's market expansion domestically and internationally, particularly in the healthcare sector [7]. Future Directions - As a pioneer in the industrialization of AGI technology in China, Cloud Wisdom aims to leverage this award to deepen its full-stack AI technology layout and promote the integration of artificial intelligence with the real economy [7]. - The company is committed to expanding its global cooperation network and enhancing the application of AI technology across various industries to better serve societal needs [7].

Core Insights - The Chinese government has set clear policy goals for the integration of AI in healthcare, aiming for full coverage of AI diagnosis and treatment at the grassroots level by 2030, indicating a strong growth trajectory for the medical AI sector [1] - Companies like Yunzhisheng are positioned to benefit significantly from these policies, leveraging their comprehensive AI capabilities across various healthcare applications [1][5] Industry Overview - The AI healthcare market in China was valued at 97.3 billion yuan in 2023 and is projected to reach 159.8 billion yuan by 2028, with a compound annual growth rate of 10.5% from 2022 to 2028 [6] - The transition from digitalization to intelligent healthcare is evident, with the industry moving into a 3.0 phase focused on smart healthcare, enhancing service quality and accessibility [6] Company Positioning - Yunzhisheng has established a robust AI product ecosystem, integrating AI technology, medical models, and knowledge graphs, which aligns with the long-term needs of the Chinese healthcare system [6][7] - The company has developed a full-stack AI service model, enabling rapid adaptation to various healthcare scenarios and supporting innovation [3][4] Competitive Advantages - Yunzhisheng's medical AI solutions have demonstrated significant efficiency improvements, such as an 80% increase in outpatient medical record entry efficiency and a 15% reduction in doctor consultation time [4] - The company has a strong foothold in the domestic market, having created SaaS platforms that effectively integrate and utilize medical data, positioning it as a key beneficiary of policy initiatives [4][5] Future Outlook - The medical AI sector is expected to experience substantial growth, with Yunzhisheng poised to capture a significant share of the emerging market due to its comprehensive product offerings and established industry presence [6][7] - The combination of favorable policies, market demand, and technological advancements will drive the growth of the medical AI industry, with Yunzhisheng's competitive edge likely to enhance its valuation [7]